東華大學圖書館 |

語系: 繁體中文

說明(常見問題)

回圖書館首頁

手機版館藏查詢

登入

回首頁

切換: 標籤 | MARC模式 | ISBD

Single chain variable fragments: Nov...

University of Guelph (Canada).

FindBook

Google Book

Amazon

博客來

Single chain variable fragments: Novel applications as selection tools and therapeutic agents in drug discovery.

紀錄類型:	書目-電子資源 : Monograph/item
正題名/作者:	Single chain variable fragments: Novel applications as selection tools and therapeutic agents in drug discovery./
作者:	Weisser, Nina Elizabeth.
面頁冊數:	228 p.
附註:	Source: Dissertation Abstracts International, Volume: 70-03, Section: B, page: 1568.
Contained By:	Dissertation Abstracts International70-03B.
標題:	Health Sciences, General. -
電子資源:	http://pqdd.sinica.edu.tw/twdaoapp/servlet/advanced?query=NR47622
ISBN:	9780494476222

Single chain variable fragments: Novel applications as selection tools and therapeutic agents in drug discovery.
Weisser, Nina Elizabeth.

Single chain variable fragments: Novel applications as selection tools and therapeutic agents in drug discovery. - 228 p.

Source: Dissertation Abstracts International, Volume: 70-03, Section: B, page: 1568.

Thesis (Ph.D.)--University of Guelph (Canada), 2009.

Single chain variable fragment (scFv) antibodies (Abs) were used in two novel applications to broaden their utility for use in drug discovery. In the first application, scFvs were used to improve the selection of peptides that mimic carbohydrate antigens (i.e. peptide "mimotopes") for vaccination. A bottleneck in peptide mimotope discovery includes the inability of initial screening regimes to differentiate between mimotopes and non-mimotopes, thus resulting in inefficient in vivo analysis. We demonstrated a rapid screening method to identify putative mimotopes using a scFv phage-display library. The use of this screening method may increase the probability of identifying peptides that will elicit a carbohydrate cross-reactive response in vivo. A human naive scFv library was screened against both an established peptide mimotope and a non-mimotope of the Group B Streptococcus (GBS) type III polysaccharide to determine if selected antibodies cross-reacted with the original GBS polysaccharide. We were able to differentiate between these two peptides because peptide-binding Abs that cross-reacted to GBS were isolated only with the peptide mimotope. In the second application, we describe a strategy that we hypothesized would increase the therapeutic utility of scFvs by increasing their in vivo half-life and giving them the ability to enable FcgammaR-mediated effector functions towards the target antigen specified by the scFv. This increase in therapeutic utility was achieved by the non-covalent binding between epitope-tagged scFvs (e.g. 6xHis-tagged scFv) and an anti-epitope tag IgG (e.g. anti-Penta-His) that resulted in the formation of a bivalent scFv-IgG complex. To test our hypothesis we used two different murine anti-epitope tag IgG1 Abs ( i.e. anti-c-Myc and anti-Penta-His) in combination with an epitope-tagged (i.e. c-Myc and 6xHis) murine anti-Salmonella enterica serovar Typhimurium (S. Typhimurium) scFv, to examine both in vivo persistence in mice and FcR-mediated complement recruitment and phagocytosis of S. Typhimurium by the murine macrophage (Mphi)-like cell line J774. Compared to the monovalent scFv controls we demonstrated that bivalent scFv-IgG complexes can bind C1q complement, increase bacterial phagocytosis in J774 cells, and increase scFv in vivo beta-phase half-life by ca. 3-fold in a mouse model. The potential of both of these applications to increase the therapeutic utility of scFvs antibodies are discussed.

ISBN: 9780494476222Subjects--Topical Terms:

1017817
Health Sciences, General.

Single chain variable fragments: Novel applications as selection tools and therapeutic agents in drug discovery.
LDR:03332nmm 2200265 a 45 001 890709
005 20101104
008 101104s2009 ||||||||||||||||| ||eng d
020 $a 9780494476222
035 $a (UMI)AAINR47622
035 $a AAINR47622
040 $a UMI $c UMI
100 1 $a Weisser, Nina Elizabeth. $3 1064673
245 1 0 $a Single chain variable fragments: Novel applications as selection tools and therapeutic agents in drug discovery.
300 $a 228 p.
500 $a Source: Dissertation Abstracts International, Volume: 70-03, Section: B, page: 1568.
502 $a Thesis (Ph.D.)--University of Guelph (Canada), 2009.
520 $a Single chain variable fragment (scFv) antibodies (Abs) were used in two novel applications to broaden their utility for use in drug discovery. In the first application, scFvs were used to improve the selection of peptides that mimic carbohydrate antigens (i.e. peptide "mimotopes") for vaccination. A bottleneck in peptide mimotope discovery includes the inability of initial screening regimes to differentiate between mimotopes and non-mimotopes, thus resulting in inefficient in vivo analysis. We demonstrated a rapid screening method to identify putative mimotopes using a scFv phage-display library. The use of this screening method may increase the probability of identifying peptides that will elicit a carbohydrate cross-reactive response in vivo. A human naive scFv library was screened against both an established peptide mimotope and a non-mimotope of the Group B Streptococcus (GBS) type III polysaccharide to determine if selected antibodies cross-reacted with the original GBS polysaccharide. We were able to differentiate between these two peptides because peptide-binding Abs that cross-reacted to GBS were isolated only with the peptide mimotope. In the second application, we describe a strategy that we hypothesized would increase the therapeutic utility of scFvs by increasing their in vivo half-life and giving them the ability to enable FcgammaR-mediated effector functions towards the target antigen specified by the scFv. This increase in therapeutic utility was achieved by the non-covalent binding between epitope-tagged scFvs (e.g. 6xHis-tagged scFv) and an anti-epitope tag IgG (e.g. anti-Penta-His) that resulted in the formation of a bivalent scFv-IgG complex. To test our hypothesis we used two different murine anti-epitope tag IgG1 Abs ( i.e. anti-c-Myc and anti-Penta-His) in combination with an epitope-tagged (i.e. c-Myc and 6xHis) murine anti-Salmonella enterica serovar Typhimurium (S. Typhimurium) scFv, to examine both in vivo persistence in mice and FcR-mediated complement recruitment and phagocytosis of S. Typhimurium by the murine macrophage (Mphi)-like cell line J774. Compared to the monovalent scFv controls we demonstrated that bivalent scFv-IgG complexes can bind C1q complement, increase bacterial phagocytosis in J774 cells, and increase scFv in vivo beta-phase half-life by ca. 3-fold in a mouse model. The potential of both of these applications to increase the therapeutic utility of scFvs antibodies are discussed.
590 $a School code: 0081.
650 4 $a Health Sciences, General. $3 1017817
650 4 $a Health Sciences, Immunology. $3 1017716
650 4 $a Health Sciences, Pharmacology. $3 1017717
690 $a 0419
690 $a 0566
690 $a 0982
710 2 $a University of Guelph (Canada). $3 1018650
773 0 $t Dissertation Abstracts International $g 70-03B.
790 $a 0081
791 $a Ph.D.
792 $a 2009
856 4 0 $u http://pqdd.sinica.edu.tw/twdaoapp/servlet/advanced?query=NR47622